Urge to move the legs, usually accompanied by uncomfortable sensations in the legs, that begins or worsens during rest/inactivity, is partially or totally relieved by movement, and occurs primarily in the evening or night
Subjective complaints of restlessness after exposure to medication
Predominant complaint of dissatisfaction with sleep quantity/quality: ≥1 of: difficulty initiating sleep; difficulty maintaining sleep (frequent awakenings); early morning awakening with inability to return to sleep
≥3 of the following within days of stopping/reducing an antidepressant (after ≥1 month use): FINISH symptoms — flu-like; insomnia; nausea; imbalance; sensory disturbances; hyperarousal/anxiety
Dopamine antagonist exposure (antipsychotic or antiemetic) and development of severe muscle rigidity and elevated temperature
Intoxication: reversible substance-specific syndrome due to recent ingestion; Withdrawal: substance-specific syndrome due to cessation/reduction after heavy/prolonged use
Intoxication: recent cannabis use with clinically significant maladaptive behavioural/psychological changes; Withdrawal: cessation/reduction of heavy prolonged use
Excessive anxiety/worry about multiple events/activities, more days than not for ≥6 months
Involuntary movements (tardive dystonia: sustained/repetitive muscle contractions; tardive akathisia: subjective restlessness + repetitive movements) developing in association with neuroleptic use, persisting ≥4 weeks
Persistent deficits in social communication/interaction across multiple contexts (≥3 components: social-emotional reciprocity; nonverbal communicative behaviours; developing/maintaining relationships)
≥1 full manic episode (abnormally elevated/expansive/irritable mood + ↑energy, ≥7 days or any duration if hospitalised)
Hypomanic episode threshold has been met.
Recurrent binge eating episodes (eating large amount in discrete period + sense of lack of control)
≥3 of 12 catatonia symptoms: stupor; catalepsy; waxy flexibility; mutism; negativism; posturing; mannerism; stereotypy; agitation; grimacing; echolalia; echopraxia
≥2 years (≥1 yr children/adolescents) of hypomanic AND depressive symptoms not meeting full episode criteria
Disturbance of attention (reduced ability to direct, focus, sustain, shift attention) and awareness (reduced orientation to environment)
Prominent depressive episode directly attributable to physiological effects of a medical condition
Pattern of culturally inappropriate, overly familiar behaviour with relatively unfamiliar adults; ≥2 of: reduced/absent reticence; overly familiar verbal/physical behaviour; diminished checking back with caregiver; willingness to go with unfamiliar adult
Criteria met for major or mild NCD
≥5 of 9 SIG-E-CAPS symptoms for ≥2 weeks; ≥1 must be depressed mood or anhedonia
Medication-induced movement symptoms causing clinically significant distress or impairment
Symptoms characteristic of a feeding/eating disorder causing clinically significant distress/impairment
Criteria met for a personality disorder (enduring pattern of inner experience/behaviour deviating markedly from cultural expectations; pervasive; inflexible; stable; leading to distress/impairment)
Symptoms characteristic of a schizophrenia spectrum/other psychotic disorder causing clinically significant distress/impairment
Symptoms characteristic of a trauma/stressor-related disorder causing clinically significant distress/impairment
Depressed mood most of the day, more days than not, for ≥2 years (≥1 yr children/adolescents)
≥5 symptoms in final week before menses, improve within days of onset, become minimal/absent post-menses
Intoxication: recent sedative/hypnotic/anxiolytic use; Withdrawal: cessation/reduction after prolonged heavy use
Repetitive, seemingly driven, and apparently purposeless motor behaviour (e.g. hand shaking/waving, body rocking, head banging, self-biting, hitting own body)
Involuntary athetoid or choreiform movements (lasting ≥4 weeks) of the tongue, jaw, trunk, or extremities that developed in association with use of a neuroleptic medication